Sarepta Therapeutics Inc Update Call Transcript
Good day, and thank you for standing by. Welcome to the Sarepta Therapeutics Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Douglas Ingram, President and CEO.
Thank you, Josh. Good afternoon, everyone, and thank you for joining Sarepta Therapeutics call to review the top line results for EMBARK. Our double-blind, placebo-controlled study intended to confirm the benefits of ELEVIDYS in children with Duchenne. Next slide, please. We will very likely make some predictions about the future or other forward-looking statements this evening. I would ask you to please review our public filings for the various risks and uncertainties that come with those sort of forward-looking statements.
Next slide. In a moment, Dr. Rodino-Klapac will review the results and our path forward. But let me summarize at least our perspective on them now. Our perspective is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |